Banella, C.; Catalano, G.; Travaglini, S.; Pelosi, E.; Ottone, T.; Zaza, A.; Guerrera, G.; Angelini, D.F.; Niscola, P.; Divona, M.;
et al. Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. Cancers 2022, 14, 2565.
https://doi.org/10.3390/cancers14102565
AMA Style
Banella C, Catalano G, Travaglini S, Pelosi E, Ottone T, Zaza A, Guerrera G, Angelini DF, Niscola P, Divona M,
et al. Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. Cancers. 2022; 14(10):2565.
https://doi.org/10.3390/cancers14102565
Chicago/Turabian Style
Banella, Cristina, Gianfranco Catalano, Serena Travaglini, Elvira Pelosi, Tiziana Ottone, Alessandra Zaza, Gisella Guerrera, Daniela Francesca Angelini, Pasquale Niscola, Mariadomenica Divona,
and et al. 2022. "Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment" Cancers 14, no. 10: 2565.
https://doi.org/10.3390/cancers14102565
APA Style
Banella, C., Catalano, G., Travaglini, S., Pelosi, E., Ottone, T., Zaza, A., Guerrera, G., Angelini, D. F., Niscola, P., Divona, M., Battistini, L., Screnci, M., Ammatuna, E., Testa, U., Nervi, C., Voso, M. T., & Noguera, N. I.
(2022). Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. Cancers, 14(10), 2565.
https://doi.org/10.3390/cancers14102565